PRESS RELEASE published on 07/17/2025 at 09:00, 9 months 21 days ago Oxurion sécurise le financement de l'acquisition d'Axiodis CRO et projette un closing de l'opération au 1eraoût 2025 Oxurion sécurise le financement et acquiert 72% d'Axiodis CRO, renforçant sa position dans la recherche clinique. Projet d'expansion en Europe. Informations sur www.oxurion.com Acquisition Financement Europe Recherche Clinique Oxurion
BRIEF published on 07/17/2025 at 08:35, 9 months 21 days ago Oxurion Sécurise le Financement pour l'Acquisition d'Axiodis CRO Acquisition Biopharmaceutique Données Cliniques Oxurion Axiodis CRO
BRIEF published on 07/17/2025 at 08:35, 9 months 21 days ago Oxurion Secures Financing for Major Acquisition Acquisition Biopharmaceutical Clinical Data Oxurion Europe Hub
BRIEF published on 07/17/2025 at 08:35, 9 months 21 days ago Oxurion obtient un financement pour une acquisition majeure Acquisition Biopharmaceutique Données Cliniques Oxurion Plateforme Européenne
PRESS RELEASE published on 07/17/2025 at 08:30, 9 months 21 days ago Oxurion Secures Financing for the Acquisition of Axiodis CRO and Targets Closing on August 1, 2025 Oxurion NV secures financing for 72% stake in Axiodis CRO, enhancing its clinical data capabilities. Acquisition aligned with strategic roadmap for European hub. Closing set for August 1, 2025 Acquisition Clinical Data Oxurion NV Axiodis CRO European Hub
PRESS RELEASE published on 07/17/2025 at 08:30, 9 months 21 days ago Oxurion verzekert financiering voor de overname van Axiodis CRO en beoogt een closing op 1 augustus 2025 Oxurion sichert Finanzierung für die Übernahme von Axiodis CRO ab und plant Abschluss der Transaktion am 1. August 2025 Übernahme Finanzierung Oxurion Klinische Daten Therapeutische Entwicklung
BRIEF published on 07/15/2025 at 18:05, 9 months 23 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Shares Transparency Atlas Biopharmaceutical Oxurion
BRIEF published on 07/15/2025 at 18:05, 9 months 23 days ago Oxurion reçoit une notification de transparence d'Atlas Special Opportunities II LLC Actions Atlas Transparence Biopharmaceutique Oxurion
PRESS RELEASE published on 07/15/2025 at 18:00, 9 months 23 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV receives transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian Transparency legislation Transparency Notification Shareholding Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
PRESS RELEASE published on 07/15/2025 at 18:00, 9 months 23 days ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV meldt ontvangst van transparantiekennisgeving en verlaagd aandelenposities onder wettelijke drempel. Biofarmaceutisch bedrijf in Leuven actief op gebied van therapeutische innovatie en klinisch onderzoek Transparantiekennisgeving Euronext Brussel Oxurion NV Leuven Biofarmaceutisch
Published on 05/08/2026 at 00:00, 21 minutes ago Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Published on 05/07/2026 at 23:30, 51 minutes ago Faraday Copper Reports First Quarter 2026 Financial Results
Published on 05/07/2026 at 23:15, 1 hour 6 minutes ago BULGOLD Adopts Semi-Annual Financial Reporting
Published on 05/07/2026 at 22:05, 2 hours 16 minutes ago MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications
Published on 05/07/2026 at 22:05, 2 hours 16 minutes ago Innodata Reports Record First Quarter 2026 Results
Published on 05/07/2026 at 23:23, 57 minutes ago H1 25/26: Challenging environment and significant changes in IT market // Revised forecast // Programme to boost competitiveness
Published on 05/07/2026 at 23:14, 1 hour 6 minutes ago EQS-Adhoc: All for One Group SE revises forecast for 2025/26 financial year // »Precision« programme to boost competitiveness approved
Published on 05/07/2026 at 22:05, 2 hours 15 minutes ago Univar Solutions Announces Leadership Evolution
Published on 05/07/2026 at 20:42, 3 hours 38 minutes ago RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
Published on 05/07/2026 at 18:46, 5 hours 35 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/07/2026 at 19:15, 5 hours 6 minutes ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 5 hours 6 minutes ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 5 hours 14 minutes ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 5 hours 14 minutes ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 5 hours 21 minutes ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL